BBNX · Beta Bionics, Inc. · Financials
Market Cap
$745.48M
Shares
44.99M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$100.25M
+53.9%
FY2025
Net Income
-$73.2M
-33.7%
FY2025
Gross Margin
55.4%
+0.3pp
FY2025
Operating Margin
-71.5%
-2pp
FY2025
Diluted EPS
-$1.81
+79%
FY2025
Operating Cash Flow
-$50.93M
-5.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| $131M – $136M | $119.01M | $100.25M | $65.12M | $12M | |
| — | $49.61M | $44.71M | $29.24M | $5.69M | |
| — | $69.4M | $55.54M | $35.89M | $6.31M | |
| — | — | 55.4% | 55.11% | 52.59% | |
| — | $38.92M | $34.79M | $26.18M | $17.94M | |
| — | $77.75M | $61.4M | $37.09M | $11.99M | |
| — | $35.74M | $31.03M | $17.87M | $12.23M | |
| — | $152.42M | $127.22M | $81.14M | $42.16M | |
| — | -$83.02M | -$71.68M | -$45.25M | -$35.85M | |
| — | — | -71.5% | -69.48% | -298.87% | |
| — | $10.04M | $10.93M | $3.91M | $1.78M | |
| — | $10.04M | -$1.52M | -$9.51M | -$8.25M | |
| — | — | $0 | $0 | — | |
| — | -$72.97M | -$73.2M | -$54.76M | -$44.1M | |
| — | — | -73.02% | -84.08% | -367.64% | |
| — | -$73.51M | -$72.86M | -$54.83M | -$43.96M | |
| USD/shares | — | -$1.51 | -$1.81 | -$8.60 | -$8.31 |
| USD/shares | — | -$1.51 | -$1.81 | -$8.60 | -$8.31 |
| shares | — | — | 40.53M | 6.37M | 5.3M |
| shares | — | — | 40.53M | 6.37M | 5.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.50×
EV/EBIT
—
Peer median 22.12×
P/E (TTM)
—
Peer median 23.74×
Peer medians compare against the 69 similar-size Medical Devices companies (of 150 listed).
Key facts
CIK
1674632
CUSIP
08659B102
13F (30d)
55 filings
55 filers
Visit website
Investor relations